Mirae Asset Global Etfs Holdings Ltd. Nurix Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 29,575 shares of NRIX stock, worth $832,240. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,575Holding current value
$832,240% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NRIX
# of Institutions
186Shares Held
67.2MCall Options Held
40.9KPut Options Held
106K-
Black Rock Inc. New York, NY6.82MShares$192 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.42MShares$124 Million6.02% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.99MShares$112 Million2.73% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$109 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$102 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.33B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...